SUBJECTS : Biliary Tract Diseases | Liver Disease
Clinical and Molecular Hepatology: 2023, vol: 29, issue: 3
- 1)- Yuri Cho, Jin Woo Choi, Hoon Kwon, Kun Yung Kim, Byung Chan Lee, Hee Ho Chu, Dong Hyeon Lee, Han Ah Lee, Gyoung Min Kim, Jung Suk Oh, Dongho Hyun, In Joon Lee, Hyunchul Rhim, . Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association. Clinical and molecular hepatology. 2023, 29 (3): 521-541
Cited : 7Read More - 2)- Xianhua Mao, Lung Yi Mak, Wai-Kay Seto. The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B. Clinical and molecular hepatology. 2023, 29 (3): 690-692Cited : 1Read More
- 3)- Moon Haeng Hur, Yuri Cho, Do Young Kim, Jae Seung Lee, Gyoung Min Kim, Hyo-Cheol Kim, Dong Hyun Sinn, Dongho Hyun, Han Ah Lee, Yeon Seok Seo, In Joon Lee, Joong-Won Park, Yoon Jun Kim. Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis. Clinical and molecular hepatology. 2023, 29 (3): 763-778Cited : 3Read More
- 4)- Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee. Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma. Clinical and molecular hepatology. 2023, 29 (3): 794-809Cited : 1Read More
- 5)- Hassam Ali. Letter 1 regarding "Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma". Clinical and molecular hepatology. 2023, 29 (3): 813-814Cited : 0Read More
- 6)- Amnuay Kleebayoon, Viroj Wiwanitkit. Letter 2 regarding "Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma". Clinical and molecular hepatology. 2023, 29 (3): 815-816Cited : 1Read More
- 7)- Seul Ki Han, Soon Koo Baik, Moon Young Kim. Correspondence on Letter regarding "Non-alcoholic fatty liver disease: Definition and subtypes". Clinical and molecular hepatology. 2023, 29 (3): 817-819Cited : 0Read More
- 8)- Joo Hyun Oh, Dong Hyun Sinn. Correspondence on Letter regarding "Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?". Clinical and molecular hepatology. 2023, 29 (3): 820Cited : 0Read More
- 9)- Yee Hui Yeo, Jamil S Samaan, Wee Han Ng. Correspondence on Letter 1 regarding "Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma". Clinical and molecular hepatology. 2023, 29 (3): 821-822Cited : 2Read More
- 10)- Yee Hui Yeo, Jamil S Samaan, Wee Han Ng. Correspondence on Letter 2 regarding "Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma". Clinical and molecular hepatology. 2023, 29 (3): 823-824Cited : 2Read More
- 11)- Soon Kyu Lee, Jung Hyun Kwon. HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations? Clinical and molecular hepatology. 2023, 29 (3): 825-827Cited : 0Read More
- 12)- Joo Hyun Oh, Dong Hyun Sinn. Erratum to 'Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?' [Clin Mol Hepatol 2023;29:367-370]. Clinical and molecular hepatology. 2023, 29 (3): 828-829Cited : 0Read More
- 13)- Kyung-Ah Kim, Sejoon Lee, Hye Jung Park, Eun Sun Jang, Youn Jae Lee, Sung Bum Cho, Young Seok Kim, In Hee Kim, Byung Seok Lee, Woo Jin Chung, Sang Hoon Ahn, Seungtaek Kim, Sook Hyang Jeong. Erratum to 'Next-generation sequencing analysis of hepatitis C virus resistance-associated substitutions in directacting antiviral failure in South Korea' [Clin Mol Hepatol 2023;29:496-509]. Clinical and molecular hepatology. 2023, 29 (3): 830Cited : 0Read More
